Brief: Design Therapeutics Q3 Basic EPS USD -0.23
07/11/2024 21:01
Nov 07 (Reuters) - Design Therapeutics Q3 net income USD -13.039 million. * Q3 operating income USD -16.246 million * Q3 operating expenses USD 16.246 million
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1